

March 27, 2025

Press Release

TOWA PHARMACEUTICAL CO., LTD.

**Manufacture and sales approval obtained for Japan's first extended-release Rivastigmine transdermal formulation (twice-weekly dosage),
“RIVALUEN® LA Patch 25.92 mg / 51.84 mg”**

Osaka, Japan, March 27, 2025 – Towa Pharmaceutical Co., Ltd. (Towa) is pleased to announce that it has obtained manufacture and sales approval for Japan's first extended-release therapeutic patch for Alzheimer's type dementia, “RIVALUEN® LA Patch 25.92 mg / 51.84 mg” (nonproprietary name: Rivastigmine) as a new drug, under the indication or efficacy of “suppression of progression of dementia symptoms in mild to moderate Alzheimer's disease,” as of today, March 27.

This formulation is an extended-release transdermal patch (twice-weekly dosage) containing Rivastigmine as an API, developed by Luye Pharma Switzerland AG from Switzerland. This approval is based on the results of a Phase III clinical trial conducted in Japan for mild to moderate Alzheimer's type dementia in which Towa Pharmaceutical introduced this formulation under an exclusive development and sales agreement. In the Phase III clinical trial conducted in Japan, a double-blind controlled study was implemented using a once-daily Rivastigmine patch as a control drug to verify the non-inferiority of this drug.

Patches visualize a medication status and are expected as a way to improve adherence that reduces burden on caregivers who manage the medication status. In contrast to current treatments for Alzheimer's type dementia, which require one or two doses daily, this formulation reduces the dosing frequency to twice weekly, thereby expected to further reduce the burden of medication management.

Towa Pharmaceutical aims to contribute to realizing sustainable dementia care and supporting patients, their families, and those engaged in their care by providing a better quality of life. Under the Towa Philosophy, “We contribute to people's health. We are dedicated to people's genuine smiles,” we will continue to strive to become a company that is always needed by society and local communities and to meet the needs of patients, caregivers, and medical professionals.



[Reference]

Product overview

Product name	RIVALUEN® LA Patch 25.92 mg RIVALUEN® LA Patch 51.84 mg
Nonproprietary name	Rivastigmine
Indication or efficacy	Suppression of progression of dementia symptoms in mild to moderate Alzheimer's disease
Dosage and administration	In general, for adults, administer 25.92 mg of Rivastigmine as a starting dose. Increase to 51.84 mg as a maintenance dose four weeks later in principle. Apply the patch to normal healthy skin on the back, upper arm, or chest. In principle, apply a patch for four days at start and replace the patch every three or four days (twice weekly).

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Email: kouhou@towayakuhin.co.jp